Renal cell carcinoma: Current status and future directions

Critical Reviews in Oncology/Hematology

Volumn 45, Issue 2, 2003, Pages 177-190

  Martel, Cynthia L ^a   Lara Jr , Primo N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Renal cell carcinoma; Treatment

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYTOKINE; INTERFERON; INTERLEUKIN 2; TUMOR VACCINE;

ANGIOGENESIS; BIRT HOGG DUBE SYNDROME; CHEMOTHERAPY; GENETIC DISORDER; HORMONAL THERAPY; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY TUMOR; OBESITY; PAPILLARY CARCINOMA; PROGNOSIS; REVIEW; RISK FACTOR; SCLEROSIS; SMOKING; STEM CELL TRANSPLANTATION; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 0037319717     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(02)00076-8     Document Type: Review

References (154)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J. Clin. 51:2001;15-36.
2. SEER Cancer Statistics Review 1973-1998. National Cancer Institute, 2001.
3. Cancer Incidence in Five Continents, Volume VI, IARC Scientific Publication No. 120. Lyon, France: International Agency for Research on Cancer (WHO), 1992.
4. Chow W.H., Devesa S.S., Warren J.L., Fraumeni J.F. Jr. Rising incidence of renal cell cancer in the United States. J. Am. Med. Assoc. 281:(17):1999;1628-1631.
5. Zambrano N.R., Lubensky I.A., Merino M.J., Linehan W.M., Walther M.M. Histopathology and molecular genetics of renal tumors: toward unification of a classification system. J. Urol. 162:(4):1999;1246-1258.
6. Renshaw A.A., Corless C.L. Papillary renal cell carcinoma. Histology and immunohistochemistry. Am. J. Surg. Pathol. 19:(7):1995;842-849.
7. Thoenes W., Storkel S., Rumpelt H.J. Human chromophobe cell renal carcinoma. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 48:(3):1985;207-217.
8. Srigley J.R., Eble J.N. Collecting duct carcinoma of kidney. Semin. Diagn. Pathol. 15:(1):1998;54-67.
9. Kennedy S.M., Merino M.J., Linehan W.M., Roberts J.R., Robertson C.N., Neumann R.D. Collecting duct carcinoma of the kidney. Hum. Pathol. 21:(4):1990;449-456.
10. Dimopoulos M.A., Logothetis C.J., Markowitz A., Sella A., Amato R., Ro J. Collecting duct carcinoma of the kidney. Br. J. Urol. 71:(4):1993;388-391.
11. Amin M.B., Crotty T.B., Tickoo S.K., Farrow G.M. Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases. Am. J. Surg. Pathol. 21:(1):1997;1-12.
12. Perez-Ordonez B., Hamed G., Campbell S., Erlandson R.A., Russo P., Gaudin P.B., et al. Renal oncocytoma: a clinicopathologic study of 70 cases. Am. J. Surg. Pathol. 21:(8):1997;871-883.
13. McLaughlin J.K., Mandel J.S., Blot W.J., Schuman L.M., Mehl E.S., Fraumeni J.F. Jr. A population-based case-control study of renal cell carcinoma. J. Natl. Cancer Inst. 72:(2):1984;275-284.
14. Mellemgaard A., Engholm G., McLaughlin J.K., Olsen J.H. Risk factors for renal cell carcinoma in Denmark. I. Role of socioeconomic status, tobacco use, beverages, and family history. Cancer Causes Control. 5:(2):1994;105-113.
15. Yu M.C., Mack T.M., Hanisch R., Cicioni C., Henderson B.E. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J. Natl. Cancer Inst. 77:(2):1986;351-356.
16. Asal N.R., Risser D.R., Kadamani S., Geyer J.R., Lee E.T., Cherng N. Risk factors in renal cell carcinoma: I. Methodology, demographics, tobacco, beverage use, and obesity. Cancer Detect. Prev. 11:(3-6):1988;359-377.
17. McLaughlin J.K., Gao Y.T., Gao R.N., Zheng W., Ji B.T., Blot W.J., et al. Risk factors for renal-cell cancer in Shanghai, China. Int. J. Cancer. 52:(4):1992;562-565.
18. Kreiger N., Marrett L.D., Dodds L., Hilditch S., Darlington G.A. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control. 4:(2):1993;101-110.
19. McCredie M., Stewart J.H. Risk factors for kidney cancer in New South Wales - I. Cigarette smoking. Eur. J. Cancer. 28A:(12):1992;2050-2054.
20. McLaughlin J.K., Lindblad P., Mellemgaard A., McCredie M., Mandel J.S., Schlehofer B., et al. International renal-cell cancer study. I. Tobacco use. Int. J. Cancer. 60:(2):1995;194-198.
21. Yuan J.M., Castelao J.E., Gago-Dominguez M., Yu M.C., Ross R.K. Tobacco use in relation to renal cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 7:(5):1998;429-433.
22. McLaughlin J.K., Hrubec Z., Heineman E.F., Blot W.J., Fraumeni J.F. Jr. Renal cancer and cigarette smoking in a 26-year follow up of US veterans. Public Health Rep. 105:(5):1990;535-537.
23. Hinds M.W., Kolonel L.N., Lee J., Hirohata T. Associations between cancer incidence and alcohol/cigarette consumption among five ethnic groups in Hawaii. Br. J. Cancer. 41:(6):1980;929-940.
24. Maclure M., Willett W. A case-control study of diet and risk of renal adenocarcinoma. Epidemiology. 1:(6):1990;430-440.
25. McLaughlin J.K., Lipworth L. Epidemiologic aspects of renal cell cancer. Semin. Oncol. 27:(2):2000;115-123.
26. Goodman M.T., Morgenstern H., Wynder E.L. A case-control study of factors affecting the development of renal cell cancer. Am. J. Epidemiol. 124:(6):1986;926-941.
27. Benhamou S., Lenfant M.H., Ory-Paoletti C., Flamant R. Risk factors for renal-cell carcinoma in a French case-control study. Int. J. Cancer. 55:(1):1993;32-36.
28. Yuan J.M., Castelao J.E., Gago-Dominguez M., Ross R.K., Yu M.C. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br. J. Cancer. 77:(9):1998;1508-1513.
29. Mellemgaard A., Lindblad P., Schlehofer B., Bergstrom R., Mandel J.S., McCredie M., et al. International renal-cell cancer study. III. Role of weight, height, physical activity, and use of amphetamines. Int. J. Cancer. 60:(3):1995;350-354.
30. Newsom G.D., Vugrin D. Etiologic factors in renal cell adenocarcinoma. Semin. Nephrol. 7:(2):1987;109-116.
31. McLaughlin J.K., Chow W.H., Mandel J.S., Mellemgaard A., McCredie M., Lindblad P., et al. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int. J. Cancer. 63:(2):1995;216-221.
32. Derby L.E., Jick H. Acetaminophen and renal and bladder cancer. Epidemiology. 7:(4):1996;358-362.
33. McCredie M., Pommer W., McLaughlin J.K., Stewar J.H., Lindblad P., Mandel J.S., et al. International renal-cell cancer study. II. Analgesics. Int. J. Cancer. 60:(3):1995;345-349.
34. Finkle W.D., McLaughlin J.K., Rasgon S.A., Yeoh H.H., Low J.E. Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control. 4:(6):1993;555-558.
35. Weinmann S., Glass A.G., Weiss N.S., Psaty B.M., Siscovick D.S., White E. Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am. J. Epidemiol. 140:(9):1994;792-804.
36. Heath C.W. Jr, Lally C.A., Calle E.E., McLaughlin J.K., Thun M.J. Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am. J. Epidemiol. 145:(7):1997;607-613.
37. Grove J.S., Nomura A., Severson R.K., Stemmermann G.N. The association of blood pressure with cancer incidence in a prospective study. Am. J. Epidemiol. 134:(9):1991;942-947.
38. Shapiro J.A., Williams M.A., Weiss N.S., Stergachis A., LaCroix A.Z., Barlow W.E. Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am. J. Epidemiol. 149:(6):1999;521-530.
39. Wolk A., Gridley G., Niwa S., Lindblad P., McCredie M., Mellemgaard A., et al. International renal cell cancer study. VII. Role of diet. Int. J. Cancer. 65:(1):1996;67-73.
40. Yuan J.M., Gago-Dominguez M., Castelao J.E., Hankin J.H., Ross R.K., Yu M.C. Cruciferous vegetables in relation to renal cell carcinoma. Int. J. Cancer. 77:(2):1998;211-216.
41. Mandel J.S., McLaughlin J.K., Schlehofer B., Mellemgaard A., Helmert U., Lindblad P., et al. International renal-cell cancer study. IV. Occupation. Int. J. Cancer. 61:(5):1995;601-605.
42. Enterline P.E., Hartley J., Henderson V. Asbestos and cancer: a cohort followed up to death. Br. J. Ind. Med. 44:(6):1987;396-401.
43. Maclure M. Asbestos and renal adenocarcinoma: a case-control study. Environ. Res. 42:(2):1987;353-361.
44. Boice J.D. Jr, Engholm G., Kleinerman R.A., Blettner M., Stovall M., Lisco H., et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat. Res. 116:(1):1988;3-55.
45. Asal N.R., Geyer J.R., Risser D.R., Lee E.T., Kadamani S., Cherng N. Risk factors in renal cell carcinoma. II. Medical history, occupation, multivariate analysis, and conclusions. Cancer Detect. Prev. 13:(3-4):1988;263-279.
46. Doublet J.D., Peraldi M.N., Gattegno B., Thibault P., Sraer J.D. Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J. Urol. 158:(1):1997;42-44.
47. Brennan J.F., Stilmant M.M., Babayan R.K., Siroky M.B. Acquired renal cystic disease: implications for the urologist. Br. J. Urol. 67:(4):1991;342-348.
48. MacDougall M.L., Welling L.W., Wiegmann T.B. Renal adenocarcinoma and acquired cystic disease in chronic hemodialysis patients. Am. J. Kidney Dis. 9:(2):1987;166-171.
49. Iliopoulos O., Eng C. Genetic and clinical aspects of familial renal neoplasms. Semin. Oncol. 27:(2):2000;138-149.
50. Linehan W.M., Lerman M.I., Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. J. Am. Med. Assoc. 273:(7):1995;564-570.
51. Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7:(1):1994;85-90.
52. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA. 91:(21):1994;9700-9704.
53. Walther M.M., Lubensky I.A., Venzon D., Zbar B., Linehan W.M. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J. Urol. 154:(6):1995;2010-2014.
54. Li F.P., Decker H.J., Zbar B., Stanton V.P. Jr, Kovacs G., Seizinger B.R., et al. Clinical and genetic studies of renal cell carcinomas in a family with a constitutional chromosome 3;8 translocation. Genetics of familial renal carcinoma. Ann. Intern. Med. 118:(2):1993;106-111.
55. Zbar B., Tory K., Merino M., Schmidt L., Glenn G., Choyke P., et al. Hereditary papillary renal cell carcinoma. J. Urol. 151:(3):1994;561-566.
56. Zbar B., Glenn G., Lubensky I., Choyke P., Walther M.M., Magnusson G., et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J. Urol. 153:(3.2):1995;907-912.
57. Schmidt L., Duh F.M., Chen F., Kishida T., Glenn G., Choyke P., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16:(1):1997;68-73.
58. Toro J.R., Glenn G., Duray P., Darling T., Weirich G., Zbar B., et al. Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch. Dermatol. 135:(10):1999;1195-1202.
59. Javidan J., Stricker H.J., Tamboli P., Amin M.B., Peabody J.O., Deshpande A., et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J. Urol. 162:(4):1999;1277-1281.
60. Ritchie A.W., deKernion J.B. The natural history and clinical features of renal carcinoma. Semin. Nephrol. 7:(2):1987;131-139.
61. Grimaldi G., Reuter V., Russo P. Bilateral non-familial renal cell carcinoma. Ann. Surg. Oncol. 5:(6):1998;548-552.
62. Mevorach R.A., Segal A.J., Tersegno M.E., Frank I.N. Renal cell carcinoma: incidental diagnosis and natural history: review of 235 cases. Urology. 39:(6):1992;519-522.
63. Konnak J.W., Grossman H.B. Renal cell carcinoma as an incidental finding. J. Urol. 134:(6):1985;1094-1096.
64. Skinner D.G., Colvin R.B., Vermillion C.D., Pfister R.C., Leadbetter W.F. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer. 28:(5):1971;1165-1177.
65. Blay J.Y., Rossi J.F., Wijdenes J., Menetrier-Caux C., Schemann S., Negrier S., et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer. 72:(3):1997;424-430.
66. Wechsel H.W., Feil G., Lahme S., Zumbragel A., Petri E., Bichler K.H. Control of hepatic parameters in renal cell carcinoma (RCC) by interleukin-6 (IL-6). Anticancer Res. 19:(4A):1999;2577-2581.
67. Maldazys J.D., deKernion J.B. Prognostic factors in metastatic renal carcinoma. J. Urol. 136:(2):1986;376-379.
68. Silver D.A., Morash C., Brenner P., Campbell S., Russo P. Pathologic findings at the time of nephrectomy for renal mass. Ann. Surg. Oncol. 4:(7):1997;570-574.
69. Campbell S.C., Novick A.C., Herts B., Fischler D.F., Meyer J., Levin H.S., et al. Prospective evaluation of fine needle aspiration of small, solid renal masses: accuracy and morbidity. Urology. 50:(1):1997;25-29.
70. The Complete Library of NCCN Oncology Practice Guidelines, Version 2000, 2001.
71. AJCC cancer staging handbook. 5th ed. 1998;Lippincott-Raven, Philadelphia.
72. Zisman A., Pantuck A.J., Dorey F., Said J.W., Shvarts O., Quintana D., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19:(6):2001;1649-1657.
73. Neumann H.P., Bender B.U., Berger D.P., Laubenberger J., Schultze-Seemann W., Wetterauer U., et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared with sporadic renal cell carcinoma. J. Urol. 160:(4):1998;1248-1254.
74. Hatcher P.A., Anderson E.E., Paulson D.F., Carson C.C., Robertson J.E. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J. Urol. 145:(1):1991;20-23.
75. Libertino J.A., Zinman L., Watkins E. Jr. Long-term results of resection of renal cell cancer with extension into inferior vena cava. J. Urol. 137:(1):1987;21-24.
76. Rini B.I., Vogelzang N.J. Prognostic factors in renal carcinoma. Semin. Oncol. 27:(2):2000;213-220.
77. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17:(8):1999;2530-2540.
78. Elson P.J., Witte R.S., Trump D.L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48:(24.1):1988;7310-7313.
79. Roosen J.U., Engel U., Jensen R.H., Kvist E., Schou G. Renal cell carcinoma: prognostic factors. Br. J. Urol. 74:(2):1994;160-164.
80. Wunderlich H., Schlichter A., Reichelt O., Zermann D.H., Janitzky V., Kosmehl H., et al. Real indications for adrenalectomy in renal cell carcinoma. Eur. Urol. 35:(4):1999;272-276.
81. Kardar A.H., Arafa M., Al Suhaibani H., Pettersson B.A., Lindstedt E., Hanash K.A., et al. Feasibility of adrenalectomy with radical nephrectomy. Urology. 52:(1):1998;35-37.
82. Minervini A., Lilas L., Morelli G., Traversi C., Battaglia S., Cristofani R., et al. Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery. Br. J. Urol. Int. 88:(3):2001;169-172.
83. Schafhauser W., Ebert A., Brod J., Petsch S., Schrott K.M. Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy. Anticancer Res. 19:(2C):1999;1573-1578.
84. Blom J.H., van Poppel H., Marechal J.M., Jacqmin D., Sylvester R., Schroder F.H., et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur. Urol. 36:(6):1999;570-575.
85. Russo P. Renal cell carcinoma: presentation, staging, and surgical treatment. Semin. Oncol. 27:(2):2000;160-176.
86. Novick A.C. Nephron-sparing surgery for renal cell carcinoma. Annu. Rev. Med. 53:2002;393-407.
87. Hollenbeck B.K., Wolf J.S. Jr. Laparascopic partial nephrectomy. Semin. Urol. Oncol. 19:(2):2001;123-132.
88. Zisman A., Pantuck A.J., Belldegrun A.S., Schulam P.G. Laparoscopic radical nephrectomy. Semin. Urol. Oncol. 19:(2):2001;114-122.
89. Esrig D., Ahlering T.E., Lieskovsky G., Skinner D.G. Experience with fossa recurrence of renal cell carcinoma. J. Urol. 147:(6):1992;1491-1494.
90. Finney R. The value of radiotherapy in the treatment of hypernephroma - a clinical trial. Br. J. Urol. 45:(3):1973;258-269.
91. Kjaer M., Frederiksen P.L., Engelholm S.A. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int. J. Radiat. Oncol. Biol. Phys. 13:(5):1987;665-672.
92. Juusela H., Malmio K., Alfthan O., Oravisto K.J. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand. J. Urol. Nephrol. 11:(3):1977;277-281.
93. Basting R., Corvin S., Handel D., Hinke A., Schmidt D. Adjuvant immunotherapy in renal cell carcinoma - comparison of interferon alpha treatment with an untreated control. Anticancer Res. 19:(2C):1999;1545-1548.
94. Pizzocaro G., Piva L., Colavita M., Ferri S., Artusi R., Boracchi P., et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol. 19:(2):2001;425-431.
95. Trump D.L., Elson P., Propert K., Pontes J., Crawford E., Wilding G., et al. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma (HR-RCC). Proc. Am. Soc. Clin. Oncol. 15:1996;253.
96. Blachere N.E., Udono H., Janetzki S., Li Z., Heike M., Srivastava P.K. Heat shock protein vaccines against cancer. J. Immunother. 14:(4):1993;352-356.
97. Kavolius J.P., Mastorakos D.P., Pavlovich C., Russo P., Burt M.E., Brady M.S. Resection of metastatic renal cell carcinoma. J. Clin. Oncol. 16:(6):1998;2261-2266.
98. Sandock D.S., Seftel A.D., Resnick M.I. A new protocol for the follow up of renal cell carcinoma based on pathological stage. J. Urol. 154:(1):1995;28-31.
99. Levy D.A., Slaton J.W., Swanson D.A., Dinney C.P. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J. Urol. 159:(4):1998;1163-1167.
100. Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. New Engl. J. Med. 345:(23):2001;1655-1659.
101. Mickisch G.H., Garin A., van Poppel H., de Prijck L., Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 358:(9286):2001;966-970.
102. DiBiase S.J., Valicenti R.K., Schultz D., Xie Y., Gomella L.G., Corn B.W. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J. Urol. 158:(3.1):1997;746-749.
103. Onufrey V., Mohiuddin M. Radiation therapy in the treatment of metastatic renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 11:(11):1985;2007-2009.
104. Amato R.J. Chemotherapy for renal cell carcinoma. Semin. Oncol. 27:(2):2000;177-186.
105. Fossa S.D., Droz J.P., Pavone-Macaluso M.M., Debruyne F.J., Vermeylen K., Sylvester R. Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur. J. Cancer. 28A:(4-5):1992;878-880.
106. Hrushesky W.J., von Roemeling R., Lanning R.M., Rabatin J.T. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J. Clin. Oncol. 8:(9):1990;1504-1513.
107. Rini B.I., Vogelzang N.J., Dumas M.C., Wade J.L. III, Taber D.A., Stadler W.M. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J. Clin. Oncol. 18:(12):2000;2419-2426.
108. Fojo A.T., Shen D.W., Mickley L.A., Pastan I., Gottesman M.M. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J. Clin. Oncol. 5:(12):1987;1922-1927.
109. Warner E., Tobe S.W., Andrulis I.L., Pei Y., Trachtenberg J., Skorecki K.L. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Am. J. Clin. Oncol. 18:(3):1995;251-256.
110. Samuels B.L., Hollis D.R., Rosner G.L., Trump D.L., Shapiro C.L., Vogelzang N.J., et al. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin. Cancer Res. 3:(11):1997;1977-1984.
111. Linehan W.M., Zbar B., Bates S.E., Zelefsky M.J., Yang J.C. Cancer of the kidney and ureter. DeVita V.T. Jr, Hellman S., Rosenberg S.A. Cancer: principles and practice of oncology. 2001;1362-1396 Lippincott Williams and Wilkins, Philadelphia.
112. Snow R.M., Schellhammer P.F. Spontaneous regression of metastatic renal cell carcinoma. Urology. 20:(2):1982;177-181.
113. Oliver R.T., Miller R.M., Mehta A., Barnett M.J. A phase 2 study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression. Mol. Biother. 1:(1):1988;14-20.
114. Gleave M.E., Elhilali M., Fradet Y., Davis I., Venner P., Saad F., et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. New Engl. J. Med. 338:(18):1998;1265-1271.
115. Fossa S.D. Interferon in metastatic renal cell carcinoma. Semin. Oncol. 27:(2):2000;187-193.
116. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators, Lancet 1999;353(9146):14-7.
117. Pyrhonen S., Salminen E., Ruutu M., Lehtonen T., Nurmi M., Tammela T., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 17:(9):1999;2859-2867.
118. Fossa S.D., Kramar A., Droz J.P. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur. J. Cancer. 30A:(9):1994;1310-1314.
119. Motzer R.J., Rakhit A., Ginsberg M., Rittweger K., Vuky J., Yu R., et al. Phase I trial of 40-kDa branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J. Clin. Oncol. 19:(5):2001;1312-1319.
120. Margolin K.A. Interleukin-2 in the treatment of renal cancer. Semin. Oncol. 27:(2):2000;194-203.
121. Fisher R.I., Rosenberg S.A., Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6:(Suppl 1):2000;S55-S57.
122. Kammula U.S., White D.E., Rosenberg S.A. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 83:(4):1998;797-805.
123. West W.H., Tauer K.W., Yannelli J.R., Marshall G.D., Orr D.W., Thurman G.B., et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New Engl. J. Med. 316:(15):1987;898-905.
124. Yang J.C., Rosenberg S.A. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J. Sci. Am. 3:(Suppl 1):1997;S79-S84.
125. Atkins M.B., Sparano J., Fisher R.I., Weiss G.R., Margolin K.A., Fink K.I., et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J. Clin. Oncol. 11:(4):1993;661-670.
126. Marincola F.M., White D.E., Wise A.P., Rosenberg S.A. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J. Clin. Oncol. 13:(5):1995;1110-1122.
127. Rosenberg S.A., Lotze M.T., Yang J.C., Linehan W.M., Seipp C., Calabro S., et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol. 7:(12):1989;1863-1874.
128. Atzpodien J., Lopez H.E., Kirchner H., Bodenstein H., Pfreundschuh M., Rebmann U., et al. Multiinstitutional home-therapy trial of recombinant human interleukin- 2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J. Clin. Oncol. 13:(2):1995;497-501.
129. Negrier S., Escudier B., Lasset C., Douillard J.Y., Savary J., Chevreau C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. New Engl. J. Med. 338:(18):1998;1272-1278.
130. Jayson G.C., Middleton M., Lee S.M., Ashcroft L., Thatcher N. A randomized phase II trial of interleukin 2 and interleukin 2- interferon alpha in advanced renal cancer. Br. J. Cancer. 78:(3):1998;366-369.
131. McDermott D., Flaherty L., Clark J., Weiss G., Logan T., Gordon M., et al. A randomized phase III trial of high-dose interleukin-2 (HD IL2) versus subcutaneous (SC) IL2/interferon (IFN) in patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 20:2001;172a.
132. Dutcher J.P., Atkins M., Fisher R., Weiss G., Margolin K., Aronson F., et al. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Cancer J. Sci. Am. 3:(Suppl 1):1997;S73-S78.
133. Lissoni P., Rovelli F., Baiocco N., Tangini G., Fumagalli L. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone. Anticancer Res. 21:(1B):2001;777-779.
134. Atzpodien J., Kirchner H., Hanninen E.L., Deckert M., Fenner M., Poliwoda H. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur. J. Cancer. 29A:(Suppl 5):1993;S6-S8.
135. Ellerhorst J.A., Sella A., Amato R.J., Tu S.M., Millikan R.E., Finn L.D., et al. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer. 80:(11):1997;2128-2132.
136. Hofmockel G., Langer W., Theiss M., Gruss A., Frohmuller H.G. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J. Urol. 156:(1):1996;18-21.
137. Joffe J.K., Banks R.E., Forbes M.A., Hallam S., Jenkins A., Patel P.M., et al. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br. J. Urol. 77:(5):1996;638-649.
138. Ravaud A., Audhuy B., Gomez F., Escudier B., Lesimple T., Chevreau C., et al. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. J. Clin. Oncol. 16:(8):1998;2728-2732.
139. Tourani J.M., Pfister C., Berdah J.F., Benhammouda A., Salze P., Monnier A., et al. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. J. Clin. Oncol. 16:(7):1998;2505-2513.
140. Negrier S., Caty A., Lesimple T., Douillard J.Y., Escudier B., Rossi J.F., et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J. Clin. Oncol. 18:(24):2000;4009-4015.
141. Law T.M., Motzer R.J., Mazumdar M., Sell K.W., Walther P.J., O'Connell M., et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 76:(5):1995;824-832.
142. Figlin R, Thompson J, Roudet C, Lange P, Belldegrun A. Multi-center randomized placebo controlled phase II/III trial of CD8(+) tumor infiltrating lymphocyte therapy (CD8(+) TIL)/recombinant interleukin-2 (IL-2) in metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 1998;17;318a.
143. Kugler A., Stuhler G., Walden P., Zoller G., Zobywalski A., Brossart P., et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6:(3):2000;332-336.
144. Divgi C.R., Bander N.H., Scott A.M., O'Donoghue J.A., Sgouros G., Welt S., et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin. Cancer Res. 4:(11):1998;2729-2739.
145. Li Z., Amato R., Papandreou C., Pagliaro L., Kim J., Millikan R., et al. Phase II study of thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin-2 (IL-2)-based therapy (Rx). Proc. Am. Soc. Clin. Oncol. 20:2001;180a.
146. Vuky J., Berg W., Yu R., Ginsberg M., Mazumdar M., Bacik J., et al. Phase II trial of thalidomide in patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 20:2001;265a.
147. Novik Y., Dutcher J.P., Larkin M., Wiernik P.H. Phase II study of thalidomide (T) in advanced refractory metastatic renal cell cancer (MRCC): a single institution experience. Proc. Am. Soc. Clin. Oncol. 20:2001;265a.
148. Srinivas S. A randomized trial of two dosing schedules of oral thalidomide in metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 20:2001;159b.
149. Nathan P.D., Walker D., Bridle H., Ross P., Stevenson A., Lee S.M., et al. A phase II study investigating the use of thalidomide in conjunction with interferon-alpha in patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 20:2001;265a.
150. Senderowicz A.M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest. New Drugs. 17:(3):1999;313-320.
151. Stadler W.M., Vogelzang N.J., Amato R., Sosman J., Taber D., Liebowitz D., et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J. Clin. Oncol. 18:(2):2000;371-375.
152. Arguello F., Alexander M., Sterry J.A., Tudor G., Smith E.M., Kalavar N.T., et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood. 91:(7):1998;2482-2490.
153. Childs R., Drachenberg D. Allogeneic stem cell transplantation for renal cell carcinoma. Curr. Opin. Urol. 11:(5):2001;495-502.
154. Childs R., Chernoff A., Contentin N., Bahceci E., Schrump D., Leitman S., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. New Engl. J. Med. 343:(11):2000;750-758.